Sonika Dahiya

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5069540/publications.pdf

Version: 2024-02-01

94381 74108 6,328 155 37 citations h-index papers

g-index 158 158 158 10895 docs citations times ranked citing authors all docs

75

#	Article	IF	CITATIONS
1	RNA sequence analysis reveals ITGAL/CD11A as a stromal regulator of murine low-grade glioma growth. Neuro-Oncology, 2022, 24, 14-26.	0.6	17
2	Microstructural Periventricular White Matter Injury in Post-hemorrhagic Ventricular Dilatation. Neurology, 2022, 98, .	1.5	8
3	Multivariate analysis of associations between clinical sequencing and outcome in glioblastoma. Neuro-Oncology Advances, 2022, 4, vdac002.	0.4	3
4	Genetic and histopathological associations with outcome in pediatric pilocytic astrocytoma. Journal of Neurosurgery: Pediatrics, 2022, 29, 504-512.	0.8	3
5	A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome. Blood Advances, 2022, 6, 3189-3193.	2.5	7
6	Loss of H3K27 Trimethylation Promotes Radiotherapy Resistance in Medulloblastoma and Induces an Actionable Vulnerability to BET Inhibition. Cancer Research, 2022, 82, 2019-2030.	0.4	9
7	Immune deconvolution and temporal mapping identifies stromal targets and developmental intervals for abrogating murine low-grade optic glioma formation. Neuro-Oncology Advances, 2022, 4, vdab194.	0.4	5
8	Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma. Neuro-Oncology, 2022, 24, 1964-1975.	0.6	15
9	Glioblastoma: Changing concepts in the WHO CNS5 classification Indian Journal of Pathology and Microbiology, 2022, 65, S24-S32.	0.1	2
10	LINC-08. Neuro-Oncology tumor board $\hat{a} \in$ one-year experience of international collaboration. Neuro-Oncology, 2022, 24, i163-i164.	0.6	0
11	HGG-34. Upfront Molecular Targeted Therapy for the Treatment of BRAF-mutant Pediatric High-Grade Glioma. Neuro-Oncology, 2022, 24, i68-i68.	0.6	1
12	GCT-06. Management of a congenital intracranial teratoma: a case report and review of literature. Neuro-Oncology, 2022, 24, i55-i55.	0.6	0
13	OTHR-15. Papillary tumor of the pineal region: case series of this rare pediatric entity. Neuro-Oncology, 2022, 24, i150-i150.	0.6	0
14	Temporal, spatial, and genetic constraints contribute to the patterning and penetrance of murine neurofibromatosis-1 optic glioma. Neuro-Oncology, 2021, 23, 625-637.	0.6	7
15	Immune cell analysis of pilocytic astrocytomas reveals sexually dimorphic brain region-specific differences in T-cell content. Neuro-Oncology Advances, 2021, 3, vdab068.	0.4	2
16	Normalization of electroretinogram and symptom resolution of melanoma-associated retinopathy with negative autoantibodies after treatment with programmed death-1 (PD-1) inhibitors for metastatic melanoma. Cancer Immunology, Immunotherapy, 2021, 70, 2497-2502.	2.0	7
17	Diffusion histology imaging differentiates distinct pediatric brain tumor histology. Scientific Reports, 2021, 11, 4749.	1.6	9
18	IGG4-Related Disease in the Skull Base and Calvarium: A Systematic Review and Presentation of Two Cases. , 2021, 82, .		1

#	Article	IF	Citations
19	Meningioma: A Pathology Perspective. Neurosurgery, 2021, 89, 11-21.	0.6	9
20	Chromosome 8 gain is associated with high-grade transformation in MPNST. JCI Insight, 2021, 6, .	2.3	23
21	Clinical Reasoning: A 7-Year-Old Boy With Acute-Onset Altered Mental Status. Neurology, 2021, 96, e2774-e2778.	1.5	0
22	Biallelic <scp><i>ASCC1</i></scp> variants including a novel intronic variant result in expanded phenotypic spectrum of spinal muscular atrophy with congenital bone fractures 2 (<scp>SMABF2</scp>). American Journal of Medical Genetics, Part A, 2021, 185, 2190-2197.	0.7	4
23	Clinical and pathological characteristics of breast cancer with resected brain metastasis Journal of Clinical Oncology, 2021, 39, 1089-1089.	0.8	0
24	IgG4-Related Disease of the Skull and Skull Base–A Systematic Review and Report of Two Cases. World Neurosurgery, 2021, 150, 179-196.e1.	0.7	10
25	HGG-37. UPFRONT TARGETED THERAPY FOR THE TREATMENT OF BRAFV600E-MUTANT PEDIATRIC HIGH-GRADE GLIOMA – A MULTI-INSTITUTIONAL EXPERIENCE. Neuro-Oncology, 2021, 23, i25-i25.	0.6	0
26	Irradiation-Modulated Murine Brain Microenvironment Enhances GL261-Tumor Growth and Inhibits Anti-PD-L1 Immunotherapy. Frontiers in Oncology, 2021, 11, 693146.	1.3	5
27	EMBR-04. BET INHIBITION TARGETS RADIOTHERAPY RESISTANCE IN H3K27ME3-DEFICIENT GROUP 3 MEDULLOBLASTOMA. Neuro-Oncology, 2021, 23, i6-i6.	0.6	0
28	Sarcomatous Meningioma: Diagnostic Pitfalls and the Utility of Molecular Testing. Journal of Neuropathology and Experimental Neurology, 2021, 80, 764-768.	0.9	4
29	BRAF mutations may identify a clinically distinct subset of glioblastoma. Scientific Reports, 2021, 11, 19999.	1.6	15
30	Preferentially Expressed Antigen in Melanoma (PRAME) Expression in Malignant, but Not Benign, Peripheral Nerve Sheath Tumors. Journal of Neuropathology and Experimental Neurology, 2021, 80, 384-386.	0.9	5
31	An image processing algorithm to aid diagnosis of mesial temporal sclerosis in children: a case-control study. Pediatric Radiology, 2020, 50, 98-106.	1.1	4
32	Whole exome sequencing reveals the maintained polyclonal nature from primary to metastatic malignant peripheral nerve sheath tumor in two patients with NF1. Neuro-Oncology Advances, 2020, 2, i75-i84.	0.4	1
33	A multi-institutional analysis of clinical outcomes and patterns of care of $1p/19q$ codeleted oligodendrogliomas treated with adjuvant or salvage radiation therapy. Journal of Neuro-Oncology, 2020, 146, 121-130.	1.4	4
34	Utility of copy number variants in the classification of intracranial ependymoma. Cancer Genetics, 2020, 240, 66-72.	0.2	0
35	Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker. Acta Neuropathologica, 2020, 139, 583-596.	3.9	13
36	Prognostic impact of CDKN2A/B deletion, TERT mutation, and EGFR amplification on histological and molecular IDH-wildtype glioblastoma. Neuro-Oncology Advances, 2020, 2, vdaa126.	0.4	27

#	Article	IF	CITATIONS
37	BRAF Alteration in Central and Peripheral Nervous System Tumors. Frontiers in Oncology, 2020, 10, 574974.	1.3	15
38	Molecular and clinicopathologic features of gliomas harboring NTRK fusions. Acta Neuropathologica Communications, 2020, 8, 107.	2.4	84
39	Genomic Profiling of Circulating Tumor DNA From Cerebrospinal Fluid to Guide Clinical Decision Making for Patients With Primary and Metastatic Brain Tumors. Frontiers in Neurology, 2020, 11, 544680.	1.1	16
40	Meningioma: A Review of Clinicopathological and Molecular Aspects. Frontiers in Oncology, 2020, 10, 579599.	1.3	66
41	Diffusion Histology Imaging Combining Diffusion Basis Spectrum Imaging (DBSI) and Machine Learning Improves Detection and Classification of Glioblastoma Pathology. Clinical Cancer Research, 2020, 26, 5388-5399.	3.2	18
42	Pediatric meningioma: a clinicopathologic and molecular study with potential grading implications. Brain Pathology, 2020, 30, 1134-1143.	2.1	17
43	Dynamic 18F-FDOPA-PET/MRI for the preoperative evaluation of gliomas: correlation with stereotactic histopathology. Neuro-Oncology Practice, 2020, 7, 656-667.	1.0	5
44	Midkine activation of CD8+ T cells establishes a neuron–immune–cancer axis responsible for low-grade glioma growth. Nature Communications, 2020, 11, 2177.	5.8	83
45	Unmasking Intra-Tumoral Heterogeneity and Clonal Evolution in NF1-MPNST. Genes, 2020, 11, 499.	1.0	2
46	Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition. JCO Precision Oncology, 2020, 4, 561-571.	1.5	62
47	Update on Circumscribed Gliomas and Glioneuronal Tumors. Surgical Pathology Clinics, 2020, 13, 249-266.	0.7	5
48	Sellar Tumors. Surgical Pathology Clinics, 2020, 13, 305-329.	0.7	8
49	Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation. Oncotarget, 2020, 11, 4836-4844.	0.8	9
50	Successful Use of BRAF/MEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1590-1595.	2.3	15
51	LGG-55. OUTCOME OF BRAF V600E PEDIATRIC GLIOMAS TREATED WITH TARGETED BRAF INHIBITION. Neuro-Oncology, 2020, 22, iii377-iii377.	0.6	0
52	Histopathologic findings in malignant peripheral nerve sheath tumor predict response to radiotherapy and overall survival. Neuro-Oncology Advances, 2020, 2, vdaa131.	0.4	6
53	Telomere alterations in neurofibromatosis type 1-associated solid tumors. Acta Neuropathologica Communications, 2019, 7, 139.	2.4	12
54	Pituitary Adenoma in Pediatric and Adolescent Populations. Journal of Neuropathology and Experimental Neurology, 2019, 78, 626-632.	0.9	20

#	Article	IF	CITATIONS
55	Image Processing to Improve Detection of Mesial Temporal Sclerosis in Adults. American Journal of Neuroradiology, 2019, 40, 798-801.	1.2	3
56	Tau positron emission tomography imaging in C9orf72 repeat expansion carriers. European Journal of Neurology, 2019, 26, 1235-1239.	1.7	3
57	Heterogeneity Diffusion Imaging of gliomas: Initial experience and validation. PLoS ONE, 2019, 14, e0225093.	1.1	0
58	LGG-16. PREDICTORS OF OUTCOME IN BRAF-V600E PEDIATRIC GLIOMAS TREATED WITH BRAF INHIBITORS: A REPORT FROM THE PLGG TASKFORCE. Neuro-Oncology, 2019, 21, ii102-ii102.	0.6	0
59	Beyond sequence variation: assessment of copy number variation in adult glioblastoma through targeted tumor somatic profiling. Human Pathology, 2019, 86, 170-181.	1.1	24
60	Clinicopathologic features of anaplastic myxopapillary ependymomas. Brain Pathology, 2019, 29, 75-84.	2.1	25
61	Athymic mice reveal a requirement for T-cell–microglia interactions in establishing a microenvironment supportive of <i>Nf1</i> low-grade glioma growth. Genes and Development, 2018, 32, 491-496.	2.7	45
62	BRAF-Targeted Therapy in the Treatment of BRAF -Mutant High-Grade Gliomas in Adults. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 451-454.	2.3	6
63	Resistance-promoting effects of ependymoma treatment revealed through genomic analysis of multiple recurrences in a single patient. Journal of Physical Education and Sports Management, 2018, 4, a002444.	0.5	16
64	A rare case of endometrial cancer metastatic to the uveal choroid. Gynecologic Oncology Reports, 2018, 23, 24-27.	0.3	3
65	A 60‥earâ€Old Woman with Multifocal Subcortical Infarcts. Brain Pathology, 2018, 28, 131-132.	2.1	0
66	An 8‥earâ€Old Girl with A Supratentorial Mass. Brain Pathology, 2018, 28, 125-126.	2.1	0
67	Rapid Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With All Saraf Clinical and Radiographic Response With Combined Dabrafenib and Trametinib in Adults With Clinical Response Cancer Network: JNCCN, 2018, 16, 4-10.	2.3	60
68	Patterns of care and treatment outcomes of patients with astroblastoma: a National Cancer Database analysis. CNS Oncology, 2018, 7, CNS13.	1.2	14
69	β–III-spectrin immunohistochemistry as a potential diagnostic tool with high sensitivity for malignant peripheral nerve sheath tumors. Neuro-Oncology, 2018, 20, 858-860.	0.6	8
70	Fetal microchimerism in human brain tumors. Brain Pathology, 2018, 28, 484-494.	2.1	19
71	Comprehensive Study of the Clinical Phenotype of Germline <i>BAP1</i> Variant-Carrying Families Worldwide. Journal of the National Cancer Institute, 2018, 110, 1328-1341.	3.0	164
72	Analysis of point mutations and copy number variation in Grade II and III meningioma. Experimental and Molecular Pathology, 2018, 105, 328-333.	0.9	18

#	Article	IF	CITATIONS
73	Genetically engineered minipigs model the major clinical features of human neurofibromatosis type 1. Communications Biology, 2018, 1, 158.	2.0	49
74	Enhancing contrast to noise ratio of hippocampi affected with mesial temporal sclerosis: A case-control study in children undergoing epilepsy surgeries. Clinical Neurology and Neurosurgery, 2018, 174, 144-148.	0.6	4
75	LGG-59. REMARKABLE OBJECTIVE RESPONSE AND FAVORABLE SURVIVAL FOR BRAF-V600E CHILDHOOD LOW-GRADE GLIOMAS TO BRAF INHIBITORS COMPARED CONVENTIONAL CHEMOTHERAPY. Neuro-Oncology, 2018, 20, i117-i117.	0.6	0
76	Blood Exposure Causes Ventricular Zone Disruption and Glial Activation In Vitro. Journal of Neuropathology and Experimental Neurology, 2018, 77, 803-813.	0.9	41
77	Radiologic Response and Disease Control of Recurrent Intracranial Meningiomas Treated With Reirradiation. International Journal of Radiation Oncology Biology Physics, 2018, 102, 194-203.	0.4	14
78	Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development. Cancer Cell, 2018, 34, 163-177.e7.	7.7	145
79	Widely Metastatic Choroid Plexus Carcinoma Associated with Novel TP53 Somatic Mutation. World Neurosurgery, 2018, 119, 233-236.	0.7	4
80	Aberrant ATRX protein expression is associated with poor overall survival in NF1-MPNST. Oncotarget, 2018, 9, 23018-23028.	0.8	12
81	ATRX in Diffuse Gliomas With its Mosaic/Heterogeneous Expression in a Subset. Brain Pathology, 2017, 27, 138-145.	2.1	16
82	Dissecting Clinical Heterogeneity in Neurofibromatosis Type 1. Annual Review of Pathology: Mechanisms of Disease, 2017, 12, 53-74.	9.6	39
83	A 42‥earâ€Old Man with AIDS and Multiple Incomplete Ring Enhancing Lesions. Brain Pathology, 2017, 27, 697-698.	2.1	0
84	Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures. Oncologist, 2017, 22, 1478-1490.	1.9	176
85	Nuclear CRX and FOXJ1 Expression Differentiates Non–Germ Cell Pineal Region Tumors and Supports the Ependymal Differentiation of Papillary Tumor of the Pineal Region. American Journal of Surgical Pathology, 2017, 41, 1410-1421.	2.1	11
86	Unusual high-grade features in pediatric diffuse leptomeningeal glioneuronal tumor: comparison with a typical low-grade example. Human Pathology, 2017, 70, 105-112.	1.1	31
87	Clinical genomic profiling identifies <i>TYK2</i> mutation and overexpression in patients with neurofibromatosis type 1â€associated malignant peripheral nerve sheath tumors. Cancer, 2017, 123, 1194-1201.	2.0	25
88	Neoadjuvant Ifosfamide and Epirubicin in the Treatment of Malignant Peripheral Nerve Sheath Tumors. Sarcoma, $2017, 2017, 1-6$.	0.7	19
89	<i>KIR2DL5</i> mutation and loss underlies sporadic dermal neurofibroma pathogenesis and growth. Oncotarget, 2017, 8, 47574-47585.	0.8	8
90	Maintenance of age in human neurons generated by microRNA-based neuronal conversion of fibroblasts. ELife, $2016, 5, .$	2.8	159

#	Article	IF	Citations
91	Influence of White and Gray Matter Connections on Endogenous Human Cortical Oscillations. Frontiers in Human Neuroscience, 2016, 10, 330.	1.0	12
92	Gliosarcomas lack <i>BRAF</i> ^{V600E} mutation, but a subset exhibit β atenin nuclear localization. Neuropathology, 2016, 36, 448-455.	0.7	5
93	MNGO-16. FETAL MICROCHIMERISM IN HUMAN BRAIN TUMORS. Neuro-Oncology, 2016, 18, vi104-vi104.	0.6	O
94	An NAD ⁺ -dependent transcriptional program governs self-renewal and radiation resistance in glioblastoma. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E8247-E8256.	3.3	101
95	Performance Analysis of Various Fuzzy Clustering Algorithms: A Review. Procedia Computer Science, 2016, 79, 100-111.	1.2	88
96	Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline <i>POLE</i> Deficiency Treated with Checkpoint Blockade Immunotherapy. Cancer Discovery, 2016, 6, 1230-1236.	7.7	242
97	Molecular and histologic characteristics of pseudoprogression in diffuse gliomas. Journal of Neuro-Oncology, 2016, 130, 529-533.	1.4	26
98	Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathologica, 2016, 131, 833-845.	3.9	288
99	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. Cell, 2016, 164, 1060-1072.	13.5	702
100	Meningiomas With Rhabdoid Features Lacking Other Histologic Features of Malignancy: A Study of 44 Cases and Review of the Literature. Journal of Neuropathology and Experimental Neurology, 2016, 75, 44-52.	0.9	63
101	Spatially- and temporally-controlled postnatal p53 knockdown cooperates with embryonic Schwann cell precursor $\langle i \rangle Nf1 \langle j i \rangle$ gene loss to promote malignant peripheral nerve sheath tumor formation. Oncotarget, 2016, 7, 7403-7414.	0.8	30
102	ABCG1 maintains high-grade glioma survival <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2016, 7, 23416-23424.	0.8	18
103	Central nervous system involvement by myeloid sarcoma: a report of 12 cases and review of the literature., 2016, 35, 314-325.		16
104	Lack of BRAF-V600E Mutation in Papillary Tumor of the Pineal Region. Neurosurgery, 2015, 77, 621-628.	0.6	9
105	Aerobic Glycolysis as a Marker of Tumor Aggressiveness: Preliminary Data in High Grade Human Brain Tumors. Disease Markers, 2015, 2015, 1-11.	0.6	25
106	Whole Exome Sequencing Reveals the Order of Genetic Changes during Malignant Transformation and Metastasis in a Single Patient with NF1-plexiform Neurofibroma. Clinical Cancer Research, 2015, 21, 4201-4211.	3.2	39
107	Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas. Modern Pathology, 2015, 28, 187-200.	2.9	134
108	Subependymal giant cell astrocytoma in the absence of tuberous sclerosis complex: case report. Journal of Neurosurgery: Pediatrics, 2015, 16, 134-137.	0.8	24

#	Article	IF	CITATIONS
109	Mouse Low-Grade Gliomas Contain Cancer Stem Cells with Unique Molecular and Functional Properties. Cell Reports, 2015, 10, 1899-1912.	2.9	39
110	Posterior fossa tumor with distinct choroid plexus papilloma and ependymoma components., 2015, 34, 132-135.		3
111	Juvenile xanthogranuloma of supra-sellar region: a rare presentation., 2015, 34, 368-370.		5
112	<scp>lgG</scp> 4 Overexpression Is Rare in Meningiomas with a Prominent Inflammatory Component: A Review of 16 Cases. Brain Pathology, 2014, 24, 352-359.	2.1	13
113	Greater Extent of Resection Improves Ganglioglioma Recurrence-Free Survival in Children. Neurosurgery, 2014, 75, 37-42.	0.6	22
114	BRAFV600E mutation in sporadic and neurofibromatosis type 1-related malignant peripheral nerve sheath tumors. Neuro-Oncology, 2014, 16, 466-467.	0.6	35
115	BRAF-V600E mutation in pediatric and adult glioblastoma. Neuro-Oncology, 2014, 16, 318-319.	0.6	90
116	Clinical Outcomes of Small Cell Glioblastoma or Glioblastoma With Oligodendroglioma Component Treated With Radiation Therapy and Temozolomide. International Journal of Radiation Oncology Biology Physics, 2014, 90, S293-S294.	0.4	1
117	CELL INTRINSIC SEXUAL DIMORPHISM IN THE RB AND P21 PATHWAYS UNDERLIES MALE PREDOMINANCE IN GBM. Neuro-Oncology, 2014, 16, iii18-iii19.	0.6	0
118	BI-19 * PSEUDOPROGRESSION IN OLIGODENDROGLIOMAS AND MIXED OLIGOASTROCYTOMAS IS ASSOCIATED WITH POOR PROGNOSIS. Neuro-Oncology, 2014, 16, v27-v27.	0.6	0
119	Abstract 71: Investigating the sexually dimorphic susceptibility to brain cancer in a glioblastoma model system. , 2014, , .		1
120	Sexually dimorphic RB inactivation underlies mesenchymal glioblastoma prevalence in males. Journal of Clinical Investigation, 2014, 124, 4123-4133.	3.9	115
121	Role of magnetic resonance imaging, cerebrospinal fluid, and electroencephalogram in diagnosis of sporadic Creutzfeldt-Jakob disease. Journal of Neurology, 2013, 260, 498-506.	1.8	38
122	BRAFV600E mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathologica, 2013, 125, 901-910.	3.9	149
123	Dual Pten/Tp53 Suppression Promotes Sarcoma Progression by Activating Notch Signaling. American Journal of Pathology, 2013, 182, 2015-2027.	1.9	21
124	Diagnostic implications of IDH1-R132H and OLIG2 expression patterns in rare and challenging glioblastoma variants. Modern Pathology, 2013, 26, 315-326.	2.9	48
125	A New Approximation Algorithm for Vertex Cover Problem. , 2013, , .		1
126	Abstract 2322: TheKIAA1549:BRAFfusion gene regulates mTOR signaling and gliomagenesis in a cell typeand brain region-specific manner, 2013, , .		0

#	Article	IF	CITATIONS
127	Novel <i>BRAF </i> Alteration in a Sporadic Pilocytic Astrocytoma. Case Reports in Medicine, 2012, 2012, 1-4.	0.3	20
128	Suppression of G-protein–Coupled Receptor Kinase 3 Expression Is a Feature of Classical GBM That Is Required for Maximal Growth. Molecular Cancer Research, 2012, 10, 156-166.	1.5	35
129	Pontine Extraventricular Neurocytoma in a Child. Pediatric Neurosurgery, 2012, 48, 319-323.	0.4	4
130	Pediatric glioma-associated <i>KIAA1549:BRAF</i> expression regulates neuroglial cell growth in a cell type-specific and mTOR-dependent manner. Genes and Development, 2012, 26, 2561-2566.	2.7	84
131	Knocking down nucleolin expression in gliomas inhibits tumor growth and induces cell cycle arrest. Journal of Neuro-Oncology, 2012, 108, 59-67.	1.4	47
132	Comparative Characterization of the Human and Mouse Third Ventricle Germinal Zones. Journal of Neuropathology and Experimental Neurology, 2011, 70, 622-633.	0.9	33
133	Microproteomic analysis of 10,000 laser captured microdissected breast tumor cells using short-range sodium dodecyl sulfate-polyacrylamide gel electrophoresis and porous layer open tubular liquid chromatography tandem mass spectrometry. Journal of Chromatography A, 2011, 1218, 8168-8174.	1.8	57
134	Rethinking Pediatric Gliomas as Developmental Brain Abnormalities. Current Topics in Developmental Biology, 2011, 94, 283-308.	1.0	5
135	Pineal Tumors. Advances in Anatomic Pathology, 2010, 17, 419-427.	2.4	58
136	Gene Expression Profiles of Beta-Cell Enriched Tissue Obtained by Laser Capture Microdissection from Subjects with Type 2 Diabetes. PLoS ONE, 2010, 5, e11499.	1.1	252
137	Pertussis in India. Journal of Medical Microbiology, 2009, 58, 688-689.	0.7	4
138	Gene expression profiling of the tumor microenvironment during breast cancer progression. Breast Cancer Research, 2009, 11, R7.	2.2	547
139	Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen. Modern Pathology, 2008, 21, 925-936.	2.9	22
140	A Five-Gene Molecular Grade Index and <i>HOXB13:IL17BR</i> Are Complementary Prognostic Factors in Early Stage Breast Cancer. Clinical Cancer Research, 2008, 14, 2601-2608.	3.2	283
141	Analysis of the MammaPrint Breast Cancer Assay in a Predominantly Postmenopausal Cohort. Clinical Cancer Research, 2008, 14, 2988-2993.	3.2	140
142	HOXB13 promotes ovarian cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 17093-17098.	3.3	107
143	The Prognostic Biomarkers <i>HOXB13, IL17BR</i> , and <i>CHDH</i> Are Regulated by Estrogen in Breast Cancer. Clinical Cancer Research, 2007, 13, 6327-6334.	3.2	73
144	Frequent Met Oncogene Amplification in a Brca1/Trp53 Mouse Model of Mammary Tumorigenesis. Cancer Research, 2006, 66, 3452-3455.	0.4	37

#	Article	IF	CITATIONS
145	Stromalâ€Epithelial Gene Expression Profiles in Human Breast Cancer. FASEB Journal, 2006, 20, A222.	0.2	O
146	Spindle cell oncocytoma of the adenohypophysis: report of two cases. Acta Neuropathologica, 2005, 110, 97-99.	3.9	57
147	Response of Some Head and Neck Cancers to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors May Be Linked to Mutation of ERBB2 rather than EGFR. Clinical Cancer Research, 2005, 11, 8105-8108.	3.2	125
148	Diagnosis of Pneumocystis pneumonia by bronchoalveolar lavage cytology: experience at a tertiary care centre in India. The Indian Journal of Chest Diseases & Allied Sciences, 2005, 47, 259-65.	0.1	4
149	Allergic Fungal Sinusitis: Expanding the Clinicopathologic Spectrum. Otolaryngology - Head and Neck Surgery, 2004, 130, 209-216.	1.1	49
150	Malignant melanoma of soft parts a diagnostic pitfall in FNA: a case report. Indian Journal of Pathology and Microbiology, 2004, 47, 54-7.	0.1	1
151	Clear cell odontogenic carcinoma: a diagnostic dilemma. Pathology and Oncology Research, 2002, 8, 283-285.	0.9	22
152	Fine needle aspiration cytology of minor salivary gland tumours of the palate. Cytopathology, 2002, 13, 309-316.	0.4	24
153	Holoacardius acephalus-myelecephalus. Indian Journal of Pediatrics, 2001, 68, 783-784.	0.3	0
154	Leptomeningeal Disease and Tumor in a Murine DIPG Model: Implications for Study of the Tumor-CSF-Ependymal Microenvironment. Neuro-Oncology Advances, 0, , .	0.4	1
155	Distinguishing Tumor Admixed in a Radiation Necrosis (RN) Background: 1H and 2H MR With a Novel Mouse Brain-Tumor/RN Model. Frontiers in Oncology, 0, 12, .	1.3	8